使用以用户为中心的迭代设计流程，我们的团队开发了一个以患者为中心的适应性支持性护理系统 PatientCareAnywhere，该系统在整个护理过程中为患者提供全面的生物心理社会筛查和支持性癌症护理。 PatientCareAnywhere 的总体目标是通过赋予癌症患者自我管理技能并直接在家中为他们提供癌症护理支持来提高癌症患者的健康相关生活质量 (HRQOL) 和自我效能。这种支持适应患者的需求和健康状况，并以转诊、教育、社区资源参与和安全社交沟通等形式协调多个来源。本研究旨在评估新的基于网络的 PatientCareAnywhere 系统的可用性和与常规护理相比，检查 PatientCareAnywhere 在改善患者报告结果方面的初步功效。对于第 1 阶段，可用性测试参与者包括癌症患者 (n=4) 和护理人员 (n=7)，他们评估了软件原型并提供了定性（例如、访谈）和定量（例如系统可用性量表）反馈。在第 2 阶段，为期 3 个月的试点随机对照试验的参与者被随机分配接受 PatientCareAnywhere 干预 (n=36) 或常规护理对照条件 (n=36)。在基线（干预前评估）和基线后 12 周（干预后评估）评估 HRQOL 和癌症相关自我效能；比较两组干预前和干预后评分之间的平均差异。参与者对原型非常满意，并报告了高于平均水平的可接受可用性，平均系统可用性量表评分为 84.09 (SD 10.02)。定性数据支持干预的整体可用性和感知有用性，并根据参与者的反馈添加了一些设计功能（例如“帮助请求”功能）。在随机对照试验中，与对照组相比，干预组患者的 HRQOL 评分从干预前到干预后均有显着改善（平均差 6.08，SD 15.26）（平均差 -2.95，SD 10.63；P=.01） ）。相比之下，自我效能方面没有显着的组间差异 (P=.09)。总体而言，PatientCareAnywhere 代表了一种用户友好、实用且可接受的支持性护理干预措施，具有改善癌症患者 HRQOL 的初步功效。未来的研究需要进一步确定 PatientCareAnywhere 的功效，并探索增强用户参与度的策略，并调查干预措施的最佳强度、频率和使用，以改善患者的治疗结果。ClinicalTrials.gov NCT02408406； https://clinicaltrials.gov/study/NCT02408406.©Sharon H Baik、Karen Clark、Marisol Sanchez、Matthew Loscalzo、Ashley Celis、Marianne Razavi、Dershung Yang、William Dale、Niina Haas。最初发表于 JMIR Cancer (https://cancer.jmir.org)，2024 年 7 月 10 日。

Using an iterative user-centered design process, our team developed a patient-centered adaptive supportive care system, PatientCareAnywhere, that provides comprehensive biopsychosocial screening and supportive cancer care to patients across the continuum of care adaptively. The overarching goal of PatientCareAnywhere is to improve health-related quality of life (HRQOL) and self-efficacy of patients with cancer by empowering them with self-management skills and bringing cancer care support directly to them at home. Such support is adaptive to the patient's needs and health status and coordinated across multiple sources in the forms of referrals, education, engagement of community resources, and secure social communication.This study aims to assess the usability of the new web-based PatientCareAnywhere system and examine the preliminary efficacy of PatientCareAnywhere to improve patient-reported outcomes compared with usual care.For phase 1, usability testing participants included patients with cancer (n=4) and caregivers (n=7) who evaluated the software prototype and provided qualitative (eg, interviews) and quantitative (eg, System Usability Scale) feedback. For phase 2, participants in the 3-month pilot randomized controlled trial were randomized to receive the PatientCareAnywhere intervention (n=36) or usual care control condition (n=36). HRQOL and cancer-relevant self-efficacy were assessed at baseline (preintervention assessment) and 12 weeks from baseline (postintervention assessment); mean differences between pre- and postintervention scores were compared between the 2 groups.Participants were highly satisfied with the prototype and reported above-average acceptable usability, with a mean System Usability Scale score of 84.09 (SD 10.02). Qualitative data supported the overall usability and perceived usefulness of the intervention, with a few design features (eg, "help request" function) added based on participant feedback. With regard to the randomized controlled trial, patients in the intervention group reported significant improvements in HRQOL from pre- to postintervention scores (mean difference 6.08, SD 15.26) compared with the control group (mean difference -2.95, SD 10.63; P=.01). In contrast, there was no significant between-group difference in self-efficacy (P=.09).Overall, PatientCareAnywhere represents a user-friendly, functional, and acceptable supportive care intervention with preliminary efficacy to improve HRQOL among patients diagnosed with cancer. Future studies are needed to further establish the efficacy of PatientCareAnywhere as well as explore strategies to enhance user engagement and investigate the optimal intensity, frequency, and use of the intervention to improve patient outcomes.ClinicalTrials.gov NCT02408406; https://clinicaltrials.gov/study/NCT02408406.©Sharon H Baik, Karen Clark, Marisol Sanchez, Matthew Loscalzo, Ashley Celis, Marianne Razavi, Dershung Yang, William Dale, Niina Haas. Originally published in JMIR Cancer (https://cancer.jmir.org), 10.07.2024.